"National Institutes of Health (NIH) scientists studying an emerging coronavirus have found that a combination of two licensed antiviral drugs, ribavirin and interferon-alpha 2b, can stop the virus from replicating in laboratory-grown cells. These"...
KETEK (telithromycin) tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae, (including multi-drug resistant isolates [MDRSP*]), Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumoniae, or Mycoplasma pneumoniae, for patients 18 years old and above.
*MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae), and are isolates resistant to two or more of the following antibiotics: penicillin, 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK (telithromycin) and other antibacterial drugs, KETEK (telithromycin) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
DOSAGE AND ADMINISTRATION
The dose of KETEK (telithromycin) tablets is 800 mg (2 tablets of 400 mg) taken orally once every 24 hours, for 7–10 days. KETEK (telithromycin) tablets can be administered with or without food.
KETEK (telithromycin) may be administered without dosage adjustment in the presence of hepatic impairment.
In the presence of severe renal impairment (CLCR < 30 mL/min), including patients who need dialysis, the dose should be reduced to KETEK (telithromycin) 600 mg once daily. In patients undergoing hemodialysis, KETEK (telithromycin) should be given after the dialysis session on dialysis days. (See CLINICAL PHARMACOLOGY, Renal insufficiency.)
In the presence of severe renal impairment (CLCR < 30 mL/min), with coexisting hepatic impairment, the dose should be reduced to KETEK 400 mg once daily. (See CLINICAL PHARMACOLOGY, Multiple insufficiency.)
KETEK® (telithromycin) 400 mg tablets are supplied as light-orange, oval, film-coated tablets, imprinted “H3647” on one side and “400” on the other side. These are packaged in bottles and blister cards (Ketek (telithromycin) Pak™ and unit dose) as follows:
Bottles of 60 (NDC 0088-2225-41)
Ketek (telithromycin) Pak™, 10-tablet cards (2 tablets per blister cavity) (NDC 0088-2225-07)
Unit dose package of 100 (blister pack) (NDC 0088-2225-49)
KETEK® (telithromycin) 300 mg tablets are supplied as light-orange, oval, film-coated tablets, imprinted “38AV” on one side and blank on the other side. These are packaged in bottles as follows:
Bottles of 20 (NDC 0088-2223-20)
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].
sanofi-aventis U.S. LLC 55 Corporate Boulevard Bridgewater, New Jersey 08807 800-981-2491
Last reviewed on RxList: 1/27/2011
This monograph has been modified to include the generic and brand name in many instances.
Additional Ketek Information
Ketek - User Reviews
Ketek User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.